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Background: Natural food supplements with high flavonoid content are often claimed to promote weight-loss
and lower plasma cholesterol in animal studies, but human studies have been more equivocal. The aim of this
study was firstly to determine the effectiveness of natural food supplements containing Glycine max leaves extract
(EGML) or Garcinia cambogia extract (GCE) to promote weight-loss and lower plasma cholesterol. Secondly to
examine whether these supplements have any beneficial effect on lipid, adipocytokine or antioxidant profiles.
Methods: Eighty-six overweight subjects (Male:Female = 46:40, age: 20~50 yr, BMI > 23 < 29) were randomly
assigned to three groups and administered tablets containing EGML (2 g/day), GCE (2 g/day) or placebo (starch, 2
g/day) for 10 weeks. At baseline and after 10 weeks, body composition, plasma cholesterol and diet were assessed.
Blood analysis was also conducted to examine plasma lipoproteins, triglycerides, adipocytokines and antioxidants.
Results: EGML and GCE supplementation failed to promote weight-loss or any clinically significant change in %
body fat. The EGML group had lower total cholesterol after 10 weeks compared to the placebo group (p < 0.05).
EGML and GCE had no effect on triglycerides, non-HDL-C, adipocytokines or antioxidants when compared to
placebo supplementation. However, HDL-C was higher in the EGML group (p < 0.001) after 10 weeks compared to
the placebo group.
Conclusions: Ten weeks of EGML or GCE supplementation did not promote weight-loss or lower total cholesterol
in overweight individuals consuming their habitual diet. Although, EGML did increase plasma HDL-C levels which is
associated with a lower risk of atherosclerosis.
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Background
Obesity is a major threat to worldwide public health and
is recognized as a major factor contributing to insulin
resistance, type 2 diabetes, hyperlipidemia, hypertension,
cardiovascular disease and all-cause mortality [1,2]. A
modest weight loss in obese or overweight individuals is
reported to be associated with decreased risk of co-mor-
bidities and mortality [3]. Furthermore, reduction in
total cholesterol or low-density lipoprotein cholesterol
(LDL-C) through diet therapy or drug administration
has been shown to decrease the risk of cardiovascular
disease [4].
Natural food supplements are widely used by indivi-
duals for potential health benefits such as weight-loss
[5,6] and lower cholesterol [7-10]. However, the evi-
dence for the effectiveness of natural food supplements
to promote weight-loss and improve health is largely
derived from animal studies [5]. Therefore, it is essential
randomized double-blind placebo-controlled trials
(RCTs) are conducted to determine the effectiveness of
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improve cholesterol levels [7].
The potential health-benefits of soy supplements
have been extensively studied [7-9,11]. Soy supplemen-
tation has been reported to promote weight loss [11]
and reduce plasma cholesterol [9]. Past studies have
suggested soy may promote weight-loss via several
mechanisms including inhibition of adipogenesis, appe-
tite suppression, displacement of fat intake and
increased satiety [11]. Soy is also suggested to have an
effect on plasma cholesterol, via increased plasma
high-density lipoprotein cholesterol (HDL-C) and soy
may also protect low density lipoprotein (LDL) from
oxidation. The main flavonoids in soy, daidzein and
genistein closely mimic the chemical structure of
estrogen, therefore soy may exert biological effects via
binding to estrogen receptors [8]. Soy leaves contain
different flavonoid and polyphenol profiles compared
to soy beans, which some have suggested may provide
unique additional health benefits compared to soybean
based natural supplements [12,13]. Despite the intri-
guing evidence from in-vitro and animal studies on the
mechanisms via which soy supplements may promote
weight-loss [8] and improve plasma cholesterol [9],
RCTs have been far more equivocal [7,11] and no
RCTs have evaluated the effectiveness of a soy leaves
based supplement to promote weight-loss or lower
plasma cholesterol.
Natural food supplements containing Garcinia cambo-
gia extract (GCE) have also been widely promoted as
potential weight-loss aids and potential cholesterol low-
ering agents [5]. The effects of Garcinia cambogia have
largely been attributed to it’s rich (-)-hydroxycitric acid
(HCA) content. A recent meta-analysis of nine trials
suggested Garcinia cambogia/HCA supplementation
may cause short-term weight-loss, but the clinical rele-
vance still remains to established [14]. Several mechan-
isms have been suggested, including inhibition of energy
metabolism and appetite suppression [15]. For example,
HCA has been shown to increase the release of seroto-
nin, a neurotransmitter implicated in the regulation of
eating behaviour and appetite control [16]. Also HCA
can act directly on adipocytes, causing lipid droplet dis-
persion and altering transcription [17]. Other bioactive
components of Garginia cambogia including benzophe-
nones are reported to reduce oxidative stress levels
based on in-vitro experiments in human plasma, hence
Garginia cambogia may protect against diseases asso-
ciated with oxidative stress [18]. Garginia cambogia is
also reported to suppress cholesterol and triglyceride
accumulation in high fat diet fed mice [19]. However,
evidence that Garcinia cambogia can improve blood
lipid profiles or has antioxidant activity in humans is
lacking [20].
RCTs of the effectiveness of HCA supplements to pro-
mote weight-loss have produced equivocal findings. The
largest and most rigorous RCT to date found no signifi-
cant difference in weight-loss between HCA and placebo
supplementation [21]. Furthermore, a recent meta-analy-
sis based on nine RCTs concluded HCA supplementa-
tion may promote only minimal short-term weight-loss,
which appears to be of limited clinical relevance [14].
The aim of this study was to examine the effectiveness
of soy (Glycine max) leaves, compared to Garginia cam-
bogia or placebo supplementation on weight-loss and
plasma cholesterol in overweight individuals consuming
their habitual diet. We also examined whether either
supplement had any beneficial effect on blood adipocy-
tokines or antioxidant levels.
Methods
Subjects
Eighty six volunteers aged 20-60 years were recruited
from the local community in Daegu (population 4.1 mil-
lion), Republic of Korea. Inclusion criteria were over-
weight individuals with BMI > 23 and < 29. We used a
lower BMI cut-off for overweight individuals compared
to the World Health Organization overweight BMI cri-
teria, because some reports suggest the prevalence of
obesity related co-morbidities is higher in Asian cohort
studies at a lower BMI cut-off [22]. Exclusion criteria
included: pregnancy, smoking, serious illness, current
treatment with any medications for the control of blood
glucose levels, clinical or biochemical evidence of acute
or chronic infection, hepatic dysfunction, chronic alco-
hol consumption, regular functional food supplement
consumption which may affect the outcome of this
study or any major surgery in the 6 months prior to the
study. In addition, no subjects were actively using any
other methods for weight reduction or control of blood
lipids, including hypocaloric diet, anorexic drugs or
lipid-lowering drugs. The study was performed in accor-
dance with the Declaration of Helsinki. All subjects pro-
vided written informed consent prior to participating in
this study. The study protocol was approved by the
Kyungpook National University Human Research Com-
mittee (No. 2010-2).
Study design
The study design was a randomized, double-blind, pla-
cebo-controlled trial to determine the effectiveness of
extract of Glycine max leaves or Garcinia cambogia
extract supplementation in overweight subjects to alter
body composition, plasma cholesterol, lipids, adipocyto-
kine or antioxidant levels. The primary outcome mea-
sures were %body fat and plasma total cholesterol. The
secondary outcome measures were plasma TG, HDL-C,
non-HDL-C, %HTR, atherosclerosis index, FFA,
Kim et al. Nutrition Journal 2011, 10:94
http://www.nutritionj.com/content/10/1/94
Page 2 of 11phospholipid, Apo A-1, Apo B, Apo B/Apo A-1, antioxi-
dant enzyme activity and adipocytokine concentrations.
Subjects were randomly assigned into three nutritional
intervention groups, extract of Glycine max leaves
(EGML; n = 28), Garcinia cambogia extract (GCE; n =
29) and placebo (n = 29). Assignment of subjects to
nutritional intervention groups was conducted using
randomly generated numbers. Both subjects and investi-
gators were blinded to the nutritional intervention allo-
cated. Subjects were instructed to maintain their routine
food intake and physical activity throughout the course
of the study.
Protocol
At baseline and after the 10 week nutritional interven-
tion subjects attended the Science Research Center
laboratory at Kyungpook National University between
0 8 : 0 0a n d1 1 : 0 0ha f t e ra1 2 - 1 4ho v e r n i g h tf a s t .B l o o d
samples were drawn into heparin coated tubes, then
centrifuged at 3000× g for 15 min at 4°C and stored at
-70°C until plasma lipid, adipocytokine, antioxidant and
toxicology analysis.
Waist girth was measured at the minimum circumfer-
ence between the iliac crest and the rib cage. Hip girth
was measured at the maximum width over the greater
trochanters. Waist-to-hip ratio (WHR) was calculated as
waist girth divided by hip girth. Systolic and diastolic
blood pressure (BP) was measured using an automatic
blood pressure monitor (Omron, Japan).
Body composition was determined with the X-Scan
plus II body composition analyzer (Jawon Medical Com-
pany, Republic of Korea). The X-Scan plus II uses a 4-
point tactile electrode system that measures the total
and segmental impedance and phase angle of alternating
electric current at 8-12 different frequencies. The X-
Scan plus II software automatically calculates body com-
position based on tetrapolar bioelectrical impedance
[23] with a proprietary formula: Total body water = A ×
Height
2/Impedance + B × Weight + C × Age + D ×
Gender + E. Constants were derived from a validation
study using the isotope dilution method. Before the
body composition assessment, the subjects rested for 10
min, and then were asked to remove outer clothing
(coats, sweaters), shoes and socks. Body weight was
measured with a digital scale to the nearest 0.1 kg.
Height was assessed with a stadiometer to the nearest
0.1 cm. Subjects were instructed to stand on the instru-
ment’s foot platforms and hold the palm-and-thumb
electrodes, with their arms not touching their torso,
while body composition was determined. Day-to-day
reproducibility of bioelectrical impedance based body
composition monitors to determine %body fat is
reported to be 3.5-5% [24]. Body mass index (BMI) was
calculated as weight(kg)/height(m
2).
Food intake was recorded before and during the nutri-
tional intervention trial using a 24 h dietary recall. Sub-
jects were instructed to recall and describe the foods
and beverages consumed over the previous 24 h. Sub-
jects were asked to estimate portion sizes using com-
mon household bowls, cups and spoons. The 24 h
dietary record for each subject was coded, and standard
reference tables were used to convert estimated food
portions to weight in grams. Nutritional analysis was
performed using CAN-Pro 3.0 software (The Korean
Nutrition Society), which provides a comprehensive
database of the nutritional content of general foods and
specialty Korean foods. The 24 h diet recall method has
been reported to be a reliable and valid method to
determine daily nutritional intake, which has been used
in previous clinical trials [25,26].
Nutritional intervention
Subjects consumed either four capsules containing
EGML (2000 mg/day; Yuyu Health Care Co., Korea),
eight capsules containing GCE (2000 mg/day; 60%
hydroxyl citric acid; Newtree Inc., Korea) or four cap-
sules containing placebo (2000 mg/day starch) in the
morning and evening daily for 10 weeks. The total poly-
phenol content of EGML determined by HPLC (Shi-
madzu Corp., Japan) was 44.5 ± 2.1 mg gallic acid
equivalents/g of EGML. The compliance of subjects to
the nutritional intervention was regularly monitored
every second day by telephone during the entire study
period, all subjects reported consuming the supplement
capsules as instructed. No serious adverse effects were
reported by subjects consuming EGML, GCE or placebo
supplements. There were no subject withdrawals from
the study, therefore intention to treat analysis was not
necessary.
Plasma lipid and apolipoprotein analyses
Plasma total cholesterol (TC), triglyceride (TG), HDL-
cholesterol (HDL-C), free fatty acid (FFA) and phospho-
lipid (PL) concentrations were determined using com-
mercially available kits based on enzymatic methods
(Asan Pharm. Co., Korea). The ratio of HDL cholesterol
to total cholesterol (HTR) was calculated as [(HDL-C/
Total-Cholesterol × 100)]. Atherogenic index (AI) was
calculated by [(Total-C - HDL-C)/HDL-C], Non-HDL-C
was determined by [Total-C - HDL-C]. The apolipopro-
tin A-1 (Apo A-1) and apolipoprotein B (Apo B) were
measured using commercial assay kits (ALerCHEK. Inc,
USA).
Plasma toxicology analysis
Plasma glutamic oxaloacetic transaminase (GOT) and
glutamic pyruvic transaminase (GPT) were measured
to assess toxicity of the EGML, GCE and placebo
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determined based on enzymatic methods using com-
mercially available kits (Asan Pharm. Co., Korea).
Oxidative stress and antioxidant analysis
To determine whether EGML and GCE supplementa-
tion provided protection against oxidative stress, the
activity of the antioxidant enzymes catalase (CAT),
glutathione peroxidase (GSH-Px) and superoxide dis-
mutase (SOD) were measured in erythrocytes. To sepa-
rate erythrocytes, EDTA treated blood samples were
centrifuged at 3000× g for 15 min at 4°C. Erythrocytes
were washed three times in 0.9% NaCl, lysed and
mixed to produce a hemolysate. The hemoglobin con-
centration of the hemolysate was then estimated using
a commercial assay kit (Asan Pharm. Co. Korea). SOD
activity was measured according to the method of
Marklund and Marklund [27]. SOD activity was
expressed in unit/g hemoglobin. The CAT activity was
measured using previously published methods [28]. A
molar extinction coefficient of 0.041 (mM
-1cm
-1)w a s
used to determine the CAT activity. CAT activity was
defined as the reduction in μmol H2O2/min/g hemo-
globin. GSH-Px activity was measured using the
method described by Paglia and Valentine [29]. GSH-
Px activity was expressed as oxidized μmol NADPH/
min/g hemoglobin. As a marker of lipid peroxide pro-
duction, the plasma thiobarbituric acid-reactive sub-
stances (TBARS) concentration was measured using
the method of Tarladgis et al. [30].
Plasma adipocytokine analysis
Adiponection, adipsin, leptin, resistin, TNF-a and IL-6
were measured in plasma samples, using multiplex
detection kits (Bio-Rad, Hercules, USA). Data analyses
were performed using the Bio-Plex Manager software
version 4.1.1 (Bio-Rad, Hercules, USA).
Statistical analysis
All data are presented as mean ± S.E. Statistical analy-
sis was performed using SPSS software (version 11.5).
Significant within group changes in body composition,
plasma lipids, adipocytokine and antioxidant para-
meters between baseline and 10 weeks were assessed
using paired Student’s t-test. Significant differences
between EGML, GCE and placebo supplemented
groups at baseline and at 10 weeks were analyzed
using one-way ANOVA. Post-hoc Duncan’sm u l t i p l e
range tests were conducted when appropriate to
further examine any significant between group differ-
ences at 10 weeks. Statistically significantd i f f e r e n c e s
were accepted at p < 0.05.
Results
Baseline characteristics
Baseline characteristics of subjects were not significantly
different between EGML, GCE and placebo groups,
although, the ratio of males to females was greater in
the EGML group compared to the GCE and the placebo
group. Fasting glucose and blood pressure of all over-
weight subjects were within the normal range (Table 1).
Nutrient Intake
Baseline nutrient intake was not significantly different
between groups (Table 2). Average energy intake of the
groups was within current nutrient intake guidelines.
Fat intake constituted around 15% of total energy intake
and cholesterol intake was within the recommended
guidelines. Subjects were instructed to maintain their
habitual diet, however, 24 h diet recalls conducted dur-
ing the trial revealed significantly higher cholesterol (p <
0.05) within each group pre- (Table 2) to post-supple-
mentation (Table 3). Nevertheless there was no signifi-
cant difference in energy, protein, carbohydrate, fat or
cholesterol intake between the EGML, GCE and placebo
groups at baseline or after 10 weeks supplementation
(Table 2 and Table 3).
Effect of EGML and GCE on body composition
There were no significant differences in body weight,
body mass index (BMI) and waist-to-hip ratio (WHR)
after 10 weeks supplementation with EGML or GCE
compared to placebo (Table 4). There was a statistically
significant change in %body fat and internal fat in the
placebo group compared to both the EGML and GCE
supplemented groups (p < 0.05; Table 4). However, the
change in %body fat and internal fat was arguably of
limited clinical significance. In addition, the change in %
Table 1 Baseline clinical characteristics of subjects
Groups Placebo GCE EGML
N (male: female) 29(15:14) 29(15:14) 28(16:12)
Age (y) 33.80 ± 2.97 34.07 ± 2.30 34.96 ± 2.42
Height (cm) 169.63 ± 2.84 167.17 ± 1.58 167.95 ± 1.78
Body weight (kg) 74.03 ± 3.03 71.09 ± 2.06 72.34 ± 1.92
BMI (kg/m
2) 25.53 ± 0.43 25.29 ± 0.36 25.25 ± 0.37
Systolic BP (mmHg) 122.57 ± 4.49 125.69 ± 53 123.38 ± 4.02
Diasolic BP (mmHg) 76.85 ± 2.65 74.11 ± 3.66 75.45 ± 3.84
FBG (mg/dL) 90.04 ± 2.58 93.97 ± 3.44 88.73 ± 4.07
Waist (inch) 33.43 ± 0.69 32.43 ± 0.60 33.49 ± 0.61
Hip (inch) 39.49 ± 0.47 39.10 ± 0.42 39.54 ± 0.41
Values are mean ± S.E.; GCE, Garcinia cambogia extract; EGML, Extract of
Glycine max leaves; FBG, fasting blood glucose
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fat in the placebo group.
Effect of EGML and GCE on plasma lipid profiles
At baseline there were no significant differences in
plasma lipids between groups (Figure 1). Total choles-
terol significantly increased in the EGML, GCE and pla-
cebo groups during the course of the trial (p < 0.05;
Figure 1A). However, after 10 weeks supplementation
total cholesterol was significantly lower in the EGML
group (p < 0.05) compared to both the GCE and pla-
cebo group (Figure 1A). Plasma HDL-C concentration
was increased significantly in all groups compared to
baseline levels (p < 0.05), however after 10 weeks sup-
plementation, HDL-C was significantly higher in the
EGML compared to the placebo group (Figure 1B).
Non-HDL-C concentration was increased significantly in
only the placebo and GCE groups compared to baseline
levels (p < 0.05; Figure 1C). However, non-HDL-C was
not significantly different between groups after 10 weeks
EGML or GCE supplementation (Figure 1C). Plasma
TG was not significantly different in the EGML and
GCE group compared to the placebo group after 10
weeks (Figure 1D). Plasma FFA and the Apo B/Apo A-1
ratio were significantly lower in the EGML group after
10 weeks supplementation compared to baseline, while
%HTR level was significantly increased in the EGML
group (p < 0.05) compared to baseline (Table 5). Unfor-
tunately, neither EGML or GCE supplementation had
any significant effect on FFA, PL, %HTR, Apo A-1, Apo
B, Apo B/Apo A-1 ratio or atherosclerosis index after
10 weeks when compared to placebo (Table 5).
Effect of EGML and GCE on plasma toxicity and
erythrocyte antioxidant enzyme activity
At baseline plasma GOT and GPT activities were within
the normal healthy range across all groups (Table 6).
After 10 weeks there was no evidence of increased
plasma toxicity as a result of supplementation with
EGML or GCE compared to placebo (Table 6).
Antioxidant enzyme activity was not significantly
increased by either EGML or GCE supplementation
compared to placebo (Table 7). SOD and CAT activ-
ity remained unchanged in the EGML and GCE group
compared to baseline. Although, there were signifi-
cant differences in CAT activity between groups at
baseline which may have confounded these results.
GSH-Px activity was unchanged in the placebo group,
but significantly increased as a result of 10 weeks
EGML or GCE supplementation. However, neither
EGML nor GCE supplementation resulted in higher
GSH-Px activity compared to the placebo group. In
addition, there was no evidence EGML or GCE sup-
plementation altered oxidative stress, as plasma
TBARS content remained u n c h a n g e dc o m p a r e dt o
placebo (Table 7).
Effect of EGML and GCE on plasma adipocytokines
EGML and GCE supplementation had no effect on
plasma adiponectin, adipsin, leptin, resistin, TNF-a or
IL-6 concentrations compared to placebo (Table 8).
Although, adipsin concentrations were significantly
decreased over 10 weeks in the EGML and GCE groups
compared to baseline (p < 0.05). While leptin was signif-
icantly increased in the placebo group, but was
unchanged in the EGML and GCE groups compared to
baseline (Table 8).
Discussion
Human nutritional intervention studies are important to
evaluate the potential health benefits of natural supple-
ments suggested from evidence based on animal studies.
This study was designed to determine the effectiveness
of a Glycine max (EGML) based supplement to promote
Table 2 Baseline nutrient intake
Groups Placebo GCE EGML
Energy (Kcal/day) 2078.5 ± 96.9 1993.7 ± 102.9 2054.3 ± 118.2
Carbohydrate (g/day) 342.7 ± 51.2 338.9 ± 62.7 345.1 ± 55.8
Protein (g/day) 85.3 ± 6.7 79.7 ± 7.9 86.6 ± 4.4
Fat (g/day) 36.9 ± 4.7 35.6 ± 5.4 36.4 ± 6.9
Vit. B1 (mg/day) 1.3 ± 0.1 1.2 ± 0.1 1.1 ± 0.2
Vit. B2 (mg/day) 1.5 ± 0.1 1.2 ± 0.1 1.3 ± 0.2
Vit. C (mg/day) 61.6 ± 20.2 75.4 ± 11.8 69.6 ± 22.1
Ca (mg/day) 513.2 ± 52.9 508.1 ± 67.4 512.5 ± 57.2
Fe (mg/day) 13.8 ± 1.9 14.1 ± 1.9 12.9 ± 0.2
Cholesterol (mg/day) 223.8 ± 51.5 238.91 ± 17.0 226.66 ± 18.0
Fiber (g/day) 21.3 ± 3.6 26.5 ± 4.2 24.5 ± 0.9
Values are mean ± S.E.; GCE, Garcinia cambogia extract; EGML, Extract of
Glycine max leaves
Table 3 Nutrient intake during the nutritional
intervention
Groups Placebo GCE EGML
Energy (Kcal/day) 2456.5 ± 116.9 2357.7 ± 92.9 2436.3 ± 101.9
Carbohydrate (g/day) 411.2 ± 60.1 388.9 ± 74.4 406.6 ± 72.1
Protein (g/day) 92.3 ± 6.8 86.7 ± 7.9 89.6 ± 4.5
Fat (g/day) 49.7 ± 8.0 50.6 ± 7.7 50.1 ± 8.3
Vit. B1 (mg/day) 1.6 ± 0.1 1.4 ± 0.1 1.3 ± 0.2
Vit. B2 (mg/day) 1.8 ± 0.1 1.2 ± 0.1 1.4 ± 0.2
Vit. C (mg/day) 65.6 ± 22.2 77.2 ± 10.8 70.2 ± 12.0
Ca (mg/day) 558.2 ± 53.8 523 ± 65.0 521 ± 52.3
Fe (mg/day) 14.5 ± 1.8 16.2 ± 1.5 13.5 ± 0.5
Cholesterol (mg/day) 557.8 ± 51.5 545.5 ± 11.0 550.0 ± 18.0
Fiber (g/day) 22.5 ± 4.5 27.6 ± 3.2 23.4 ± 0.6
Values are mean ± S.E.; GCE, Garcinia cambogia extract; EGML, Extract of
Glycine max leaves
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Garcinia cambogia (GCE) or placebo supplementation.
EGML or GCE supplementation does not promote weight-
loss
The present study indicated EGML or GCE supplemen-
tation was not effective in promoting weight-loss in
overweight individuals. BMI and waist-to-hip ratio are
important risk factors associated with cardiovascular dis-
ease risk, but neither EGML supplementation nor GCE
supplementation had any significant effect on either
BMI or waist to hip ratio in the overweight individuals.
Waist to hip ratio is a crude indicator of abdominal
adiposity which represents visceral fat accumulation,
Table 4 Effect of EGML or GCE on body composition in overweight subjects
Groups Placebo GCE EGML
Before After Δ Before After Δ Before After Δ
Weight (kg) 74.03 ± 3.03 74.71 ± 3.06 0.68 ± 0.34 71.09 ± 2.06 71.73 ± 2.1 0.65 ± 0.43 72.34 ± 1.92 72.16 ± 1.97 -0.18 ± 0.30
BMI (kg/m
2) 25.53 ± 0.43 25.77 ± 0.45 0.24 ± 0.11 25.29 ± 0.36 25.53 ± 0.40 0.24 ± 0.15 25.25 ± 0.37 25.49 ± 0.39 0.24 ± 0.11
WHR 0.85 ± 0.01 0.86 ± 0.01 0.01 ± 0.01 0.83 ± 0.01 0.84 ± 0.01 0.01 ± 0.01 0.85 ± 0.01 0.84 ± 0.01 -0.01 ± 0.01
BFP (%) 25.97 ± 1.68 27.36 ± 1.48 1.39 ± 0.42
a 27.07 ± 0.76 27.74 ± 0.08 0.67 ± 0.22
b 27.81 ± 0.93 27.65 ± 1.01 -0.16 ± 0.24
b
Internal fat (kg) 2.45 ± 0.22 2.70 ± 0.23 0.25 ± 0.07
a 2.42 ± 0.11 2.56 ± 0.12 0.14 ± 0.04
b 2.54 ± 0.09 2.52 ± 0.10 -0.02 ± 0.04
b
Values are mean ± S.E.; GCE, Garcinia cambogia extract; EGML, Extract of Glycine max leaves; WHR(Waist to Hip Ratio) = Waist/Hip, BFP, Body fat percentage; Δ:
After-Before;
abMeans in the same row not sharing a common superscript are significantly different among groups at p < 0.05 by one-way ANOVA;
Figure 1 Effect of EMGL or GCE supplementation on plasma (A) total-cholesterol, (B) HDL-C, (C) non-HDL-C and (D) triglycerides.
Values are mean ± S.E. *p < 0.05 indicates a between group difference.
†p < 0.05,
††p < 0.01,
†††p < 0.001 indicates a within group difference.
GCE, Garcinia cambogia extract; EGML, Extract of Glycine max leaves.
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waist to hip ratio may not be sufficiently sensitive to
detect small changes caused by a nutritional
intervention.
Body composition parameters are more sensitive than
BMI for detecting small chang e si nb o d yf a t ,a si n d i v i -
duals with the same BMI can have a wide variability in
body fat. Indeed we found the body composition analy-
sis revealed the %body fat change was statistically lower
in the EGML and GCE supplemented group compared
to placebo after 10 weeks. However, it is important to
emphasize that a 1-1.5% body fat change is arguably of
no clinical relevance to disease risk. In addition, body
composition methods based on bioelectrical impedance
typically have day-to-day reproducibility between 3.5-5%
[31], which should be taken into consideration when
evaluating the effectiveness of natural food supplements
to promote weight-loss.
Previous studies showing soy supplementation can
promote weight-loss were mainly conducted in con-
junction with calorific restriction, and involved soy
protein with isoflavonoids [11]. In contrast in the pre-
sent study we used a soy leaves supplement which
contained abundant flavonoids but minimal protein, in
addition subjects consumed their habitual diet. On the
basis of the present findings neither EGML nor GCE
supplementation alone can promote weight-loss in
overweight individuals. These findings are in agree-
ment with the most recent meta-analyses of rando-
mized control trials of GCE or soy flavonoids which
report minimal or no effects of GCE or soy flavonoids
on weight-loss in humans [11,14]. Clearly, a natural
food based supplement which is able to promote
weight-loss would be of significant clinical benefit [5].
It is unknown whether longer EGML or GCE supple-
mentation over 6-12 months may lead to a clinically
significant reduction in body fat accumulation.
No effect of EGML or GCE supplementation on energy
intake
Natural food supplements such as EGML are pur-
ported to increase satiety, therefore may help reduce
calorie intake, but the present study and previous
human studies on soy supplementation show no effect
on satiety or calorie intake [32,33]. We actually
observed an increase in both energy and cholesterol
consumption within all groups during the study. One
explanation may have been dietary intake was under-
reported at baseline. Lack of familiarity and poor
memory may both contribute to under-reporting
when using a 24 h dietary recall [34]. A recent Eur-
opean study suggested conducting multiple dietary
recalls at baseline can help to ensure dietary recall is
reliable and reflects actual dietary intake [34].
Remarkably the increase in cholesterol intake evident
in the EGML, GCE and placebo groups over 10 weeks
was also reflected in plasma total cholesterol levels
within all groups. In agreement with past studies the
present study provided no evidence that EGML or
GCE supplementation can modify calorie intake in
overweight individuals consuming their habitual diet
[11].
Table 5 Effect of EGML or GCE on plasma lipids and atherogenic biomarkers in overweight subjects
Groups Placebo GCE EGML
Before After Before After Before After
HTR (%) 21.36 ± 1.56 22.49 ± 1.94 21.08 ± 1.48 23.14 ± 1.38 20.43 ± 1.17 23.77* ± 1.16
AI 4.51 ± 0.58 4.31 ± 0.49 4.68 ± 0.33 3.82 ± 0.31 4.14 ± 0.35 3.43 ± 0.21
FFA (mmol/L) 0.54 ± 0.04 0.50 ± 0.03 0.49 ± 0.03 0.41 ± 0.03 0.49 ± 0.03 0.40* ± 0.02
PL (mmol/L) 1.58 ± 0.05 1.53 ± 0.05 1.61 ± 0.05 1.56 ± 0.05 1.64 ± 0.06 1.56 ± 0.04
Apo A-1 ( μg/dL) 1.82 ± 0.10 1.56 ± 0.04 1.72 ± 0.08 1.85 ± 0.12 1.66 ± 0.03 1.88 ± 0.15
Apo B ( μg/dL) 4.11 ± 0.33 4.10 ± 0.34 6.27 ± 0.63 5.55 ± 0.50 5.17 ± 0.40 4.70 ± 0.37
Apo B/Apo A-1 2.26 ± 0.63 2.62 ± 0.63 3.65 ± 0.42 3.00 ± 0.29 3.11 ± 0.23 2.50* ± 0.26
Values are mean ± S.E.; *p < 0.05, **< 0.01, ***p < 0.001 indicate significant difference before and after 10 weeks by Students’ t-test; GCE, Garcinia cambogia
extract; EGML, Extract of Glycine max leaves; HTR, [HDL-C/Total-C)×100]; AI, atherogenic Index, ([(Total-C)]-[HDL-C]/[HDL-C]); FFA, free fatty; PL, phospholipid; Apo
A-1, Apolipoprotein A-1; Apo B, Apolipoprotein B.
Table 6 Effect of EGML or GCE on plasma toxicity biomarkers in overweight subjects
Groups Placebo GCE EGML
Before After Before After Before After
GOT (Karman/ml) 9.96 ± 1.45 12.73 ± 2.71 9.24 ± 1.07 8.61 ± 0.85 19.67 ± 8.86 11.23 ± 1.27
GPT (Karman/ml) 15.10 ± 3.57 15.38 ± 2.95 11.76 ± 1.50 10.15 ± 1.07 15.93 ± 2.91 15.49 ± 2.07
Values are mean ± S.E.; Data are compared between before and after 10 weeks by Students’ t-test, and between groups before and after 10 weeks by one-way
ANOVA; GCE, Garcinia cambogia extract; EGML, Extract of Glycine max leaves; GOT, glutamic oxaloacetic transaminase; GPT, glutamic pyruvic transaminase.
Kim et al. Nutrition Journal 2011, 10:94
http://www.nutritionj.com/content/10/1/94
Page 7 of 11EGML and GCE supplementation can modify plasma lipid
profiles in overweight individuals
Lowering total cholesterol, triglyceride, LDL-C or non-
HDL-C concentration is reported to decrease the risk of
developing atherosclerosis [4]. Obesity is strongly asso-
ciated with elevated plasma cholesterol and lipoproteins.
Hence natural food supplements which can significantly
improve plasma lipid profiles may be useful for choles-
terol management and prevention of atherosclerosis
[10]. In the present study, EGML supplementation
resulted in ~6% lower total plasma cholesterol com-
pared to both the GCE and placebo supplemented
groups after 10 weeks, although after 10 weeks total
plasma cholesterol was actually higher than baseline in
all groups. One explanation for the increase in total
plasma cholesterol was the increase in cholesterol intake
evident from the 24 h dietary recall analysis. The mini-
mal effect of EGML on plasma cholesterol accumulation
compared to placebo is arguably of limited clinical sig-
nificance given that total plasma cholesterol was consid-
erably higher after 10 weeks.
Plasma non-HDL-C provides a measure of multiple
lipoproteins including LDL. The lipoproteins present in
non-HDL-C are responsible for transporting cholesterol
and lipids in the blood. In the 1990’sL D L - Cw a st h e
primary target of cholesterol reduction programs [4]. A
review of clinical studies reported for every 1% reduc-
tion in LDL-C levels, relative risk for coronary heart
disease (CHD) events was reduced by approximately 1%
[4]. At baseline the overweight subjects included in this
s t u d yh a dap l a s m an o n - H D L - Cl e v e l( e q u i v a l e n tt o
LDL-C) between 122-129 mg/dl. The National Choles-
terol Education Program (NCEP) ATP III guidelines
recommend cholesterol lowering treatment in high-risk
individuals with LDL-C above 130 mg/dl [4]. During the
study, subjects consumed their habitual diet, we
observed plasma non-HDL-C actually increased in the
placebo and GCE groups to ~150 mg/dl after 10 weeks.
Inter-individual variability in non-HDL-C was evident in
all groups, which may be partly due to diet but also
genetic variation. Some overweight individuals with high
non-HDL-C are resistant to statin treatment [4], there-
fore developing nutritional interventions using natural
food supplements may provide a way to further lower
non-HDL-C and hence risk of cardiovascular disease.
Elevated plasma triglycerides in overweight patients,
are not as strongly associated with increased cardiovas-
cular risk compared to plasma cholesterol, but neverthe-
less are clinically significant as elevated plasma
triglyceride levels are an indicator of hepatosis and dysli-
pidemia [35]. In the present study neither EGML nor
GCE supplementation significantly reduced plasma tri-
glyceride levels. Although, plasma triglycerides were
~15-20% lower in the EGML and GCE groups after 10
weeks compared to baseline, again wide inter-individual
variability in plasma triglyceride levels may explain the
Table 7 Effect of EGML or GCE on erythrocyte and plasma antioxidant activity in overweight subjects
Placebo GCE EGML
Before After Before After Before After
Erythrocytes
SOD (unit/mg Hb) 2.42 ± 0.07 2.19 ± 0.12 2.42 ± 0.07 2.40 ± 0.08 2.33 ± 0.06 2.30 ± 0.08
CAT (umol/min/mg Hb) 1.38 ± 0.07
b 1.13 ± 0.10* 1.22 ± 0.06
a 1.04 ± 0.08 1.22 ± 0.05
ab 1.47 ± 0.30
GSH-Px (nmol/min/mg Hb) 2.33 ± 0.19 2.62 ± 0.27 2.16 ± 0.10 2.86 ± 0.28* 2.17 ± 0.13 2.93 ± 0.27*
Plasma
TBARS (nmol/ml) 0.26 ± 0.02 0.27 ± 0.02 0.27 ± 0.02 0.30 ± 0.02 0.23 ± 0.01 0.25 ± 0.01
Values are mean ± S.E.; *p < 0.05 Data are compared before and after 10 weeks by Students’ t-test;
abMeans not sharing same letter are significantly different
after 10 weeks between groups at p < 0.05 by one-way ANOVA; GCE, Garcinia cambogia extract; EGML, Extract of Glycine max leaves; SOD, superoxide dismutase;
CAT, catalase; GSH-Px, glutathione peroxidase; TBARS, thiobarbituric acid-reactive substances.
Table 8 Effect of EGML or GCE on plasma adipocytokines in overweight subjects
Placebo GCE EGML
Before After Before After Before After
Adiponectin ( μg/ml) 72.64 ± 4.66 72.05 ± 4.91 58.91 ± 4.45 71.25 ± 4.81 71.41 ± 5.25 69.97 ± 6.30
Adipsin ( μg/ml) 0.52 ± 0.04 0.50 ± 0.04 0.53 ± 0.03 0.43 ± 0.03* 0.56 ± 0.03 0.45 ± 0.03**
Leptin ( μg/ml) 12.64 ± 1.69 18.80 ± 2.31* 14.70 ± 1.77 14.35 ± 1.73 19.16 ± 4.81 17.89 ± 4.74
Resistin ( μg/ml) 4.42 ± 0.31 5.65 ± 0.63 4.82 ± 0.34 4.79 ± 0.48 4.31 ± 0.25 4.88 ± 0.38
TNF-a (pg/ml) 6.92 ± 0.44 7.87 ± 0.52 7.68 ± 0.55 7.26 ± 0.57 7.93 ± 0.70 7.30 ± 0.52
IL-6 (pg/ml) 9.50 ± 0.90 9.57 ± 0.81 9.07 ± 0.47 9.29 ± 0.67 8.91 ± 0.57 9.93 ± 0.55
Values are mean ± S.E.; *p < 0.05, **p < 0.01, ***p < 0.001: Data are compared before and after 10 weeks by Students’ t-test.
abMeans not sharing same letter are
significantly different after 10 weeks between groups at p < 0.05 by one-way ANOVA. GCE, Garcinia cambogia extract; EGML, Extract of Glycine max leaves.
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placebo.
Risk of cardiovascular disease is inversely associated
with plasma HDL-C concentrations and hence increased
HDL may help protect against atherosclerosis [36]. At
baseline all overweight subjects had a low HDL < 40
mg/dl based on NCEP ATP III guidelines [4]. However,
after 10 weeks the EGML group had significantly higher
plasma HDL-C levels compared to the placebo group,
and hence decreased risk of cardiovascular disease. Pro-
spective epidemiological studies have consistently indi-
cated that high levels of plasma HDL-C can protect
against the development of atherosclerosis and cardio-
vascular disease [37]. EGML appears to be effective for
increasing plasma HDL-C levels in overweight indivi-
duals. In contrast, GCE supplementation appeared to be
ineffective for raising HDL-C compared to placebo in
overweight individuals.
No evidence of toxicity after EGML or GCE
supplementation in overweight individuals
Despite the widespread use of nutritional supplements
their safety and toxicity are rarely tested in humans.
Plasma GOT and GPT activity provides an indicator of
hepatoxicity [38]. At baseline plasma GOT and GPT
activity was within the normal range and not signifi-
cantly altered by 10 weeks EGML supplementation in
overweight individuals. Furthermore, no subjects in the
study reported adverse side-effects due to EGML sup-
plementation. Nevertheless some studies have reported
that natural food supplements containing high flavonoid
doses far in excess of dietary intake may have unwanted
biological effects on absorption of other nutrients and
trace elements [39]. Potential interactions between drugs
and nutritional supplements remain largely unknown.
Therefore, it is advisable that natural food supplement
consumption in overweight individuals is supervised by
a medical physician.
EGML or GCE supplementation do not modify antioxidant
activity or adipocytokine levels in overweight individuals
Soy based supplements are reported to have antioxidant
effects in animals [40] and humans [41]. Furthermore, a
clinical study in pre- and post-menopausal Korean
women reported soy intake was inversely correlated
with oxidative stress (TBARS) [42]. Oxidative stress may
play a role in the pathogenesis of atherosclerosis, as
endothelial damage by lipid particles can lead to produc-
tion of reactive oxygen species, macrophage infiltration
and the development of an atherosclerotic plaque [43].
In the present study there was a trend for EGML to
increase CAT and GSH-Px activity in erythrocyte after
10 weeks supplementation, but these results appeared to
be confounded by inter-individual variability in
antioxidant enzyme activity. EGML and GCE supple-
mentation did not significantly effect plasma TBARS
level either which is a marker of lipid peroxidation. An
important caveat was that the overweight individuals in
this study did not show any evidence of excess oxidative
stress at baseline, compared to other human obesity stu-
dies [44]. The present findings do not preclude the pos-
sibility that EGML or GCE may possess antioxidant
activity in overweight individuals who have pre-existing
high levels of oxidative stress.
Plasma adipocytokine levels are reported to be asso-
ciated with BMI and adiposity [45]. In concordance with
the lack of clinically significant changes in body compo-
sition, we observed no change in adipocytokine levels in
the EGML or GCE group compared to placebo.
Study limitations
Firstly, the influence of sex differences on the effect of
EGML or GCE on primary and secondary outcomes was
not determined. Hormonal changes during the men-
strual cycle are a potential confounding factor in this
study. Plasma cholesterol, TG and LDL-C are reported
to vary between ~5-8% during the follicular stage [46].
To minimize potential sex differences subjects were ran-
domized into treatment and placebo groups, despite
randomization there was still an imbalance in males and
females in each group.
Secondly, it was beyond the scope of the present study
to determine whether differences in soy metabolism
between subjects in the EGML group may have influ-
enced the outcome. Some reviews suggest only 30-50%
of humans have the bacteria capable of producing equol
which is the primary metabol i t eo ft h es o yi s o f l a v o n e
daidzein [47]. Therefore, inter-individual variability in
equol activity may explain the lack of significant effects
of EGML supplementation on primary outcomes com-
pared to placebo [47].
S o yi n t a k eo fA s i a np o p u l a t i o n si sr e p o r t e dt ob e
higher than average soy intake in large European or
American cohort studies [48]. Also Garginia cambogia
is a food component used widely in South-East Asia.
Therefore, soy and GCE based supplements may have
smaller effects if any in randomized control trials con-
ducted in Asia. In agreement with previous studies on
soy and GCE supplements we used doses of 2 g/day, it
was beyond the scope of the present study to determine
whether higher doses were more effective for promoting
weight-loss and improving plasma lipid profiles.
Although, a previous report suggest higher doses may
be futile, as oral administration of higher doses of Garci-
nia cambogia extract to normal subjects leads to
increased urinary excretion of (-)-hydroxycitric acid,
attributed to limitations in (-)-hydroxycitric acid absorp-
tion efficiency [49].
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studies targeting body fat reduction that the body com-
position method has acceptable reliability and validity.
Small changes in %body fat need to be interpreted with
caution as daily or weekly intra-individual variability in
bioelectrical impedance monitors is reported to range
from 3.5-5% [31]. Furthermore, regression to the mean
may have occurred despite randomization of treatments,
and contributed to within-group and between-group
variation in baseline clinical measures and should be
considered when interpreting the findings [50,51]
Conclusions
Ten weeks EGML or GCE supplementation failed to
promote any clinically significant weight-loss and had a
minimal effect on %body fat in overweight individuals
consuming their habitual diet. Although, EGML or GCE
supplementation improved plasma HDL-C in overweight
individuals, neither EGML nor GCE had any clinically
significant effects on other plasma lipids, antioxidant or
adipocytokine levels compared to placebo. More rando-
mized human trials of natural products suggested to
improve health are essential to establish actual efficacy,
which will help to facilitate evidenced based dietary
supplementation.
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